创新药持续走强，三大核心因素驱动板块进入上行周期，创新药ETF天弘（517380）早盘涨超3.5%创本轮行情新高，且仍在持续拉升

Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a strong rally, with significant gains in stocks such as Huyou Pharmaceutical, King’s Ray Biotechnology, and Nuotai Biotechnology, which have all risen over 9% [1] - The Tianhong Innovative Drug ETF (517380) has seen a rise of over 3.5% in early trading, reaching a new high in this round of rebound, reflecting the overall market's positive sentiment towards innovative drugs [1] - Analysts predict that 2025 will mark a year of explosive growth for China's innovative drug industry, driven by three core factors: the continuous landing of significant BD transactions, leading companies turning profitable, and an improving policy environment [1] Group 2 - The Chinese innovative drug market is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [1] - There is an increasing demand for low-cost, high-quality drugs globally, prompting multinational pharmaceutical companies to seek partnerships with Chinese firms for more cost-effective innovative drug assets [1] - The release of multiple clinical data during the ASCO conference has brought additional attention and catalysts to the innovative drug sector [1] Group 3 - The Tianhong Innovative Drug ETF (517380) has achieved a cumulative increase of over 27% this year, leading all industry ETFs in market performance, outperforming the second-place ETF by approximately 10 percentage points [2] - Investors interested in the innovative drug sector may consider focusing on linked funds, specifically Class A (014564) and Class C (014565) [3]